Clinical Trial Update: Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA) [Phase 3]

View source ↗

Summary

This Phase 3 study evaluates danicopan as an add-on therapy to a C5 inhibitor in Paroxysmal Nocturnal Hemoglobinuria patients with extravascular hemolysis; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED | Results posted: 2023-07-24